Schizophrenia Trial, Recruiting NCT07379827 Sponsor: Bristol-Myers Squibb Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07379827
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You (or your caregiver or legal guardian) must be willing and able to sign a consent form agreeing to take part in the study.
  • You must be 18 years old or older and able to take part in regular medical care and follow-up visits, in your doctor's opinion.
  • You must have schizophrenia, and your doctor must have already decided — separately from this study — to treat you with the medication xanomeline and trospium chloride (also called KarXT).
  • You must either have started taking KarXT within the last 16 weeks and plan to stop your previous antipsychotic medication, OR currently be on a stable dose of one or more antipsychotic medications and have a plan to switch to KarXT (you can be enrolled even while in the process of tapering off your previous medication).
  • Other psychiatric medications (such as antidepressants or mood stabilizers) are allowed, and it is recommended that these stay at the same dose throughout the study.

Who may not be able to join:

  • You have previously tried KarXT and stopped taking it for any reason before the study begins.
  • You have taken part in another clinical trial within the last 30 days, or plan to join another interventional trial during this study.
  • You have a known allergy to xanomeline or trospium chloride, a history of or high risk of difficulty urinating, stomach emptying problems, certain liver problems, or a specific type of eye condition called narrow-angle glaucoma.
  • In your doctor's opinion, your psychiatric or physical health condition is not stable enough to safely switch to KarXT.
  • You are currently pregnant, planning to become pregnant, or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 February 2026
Est. completion
20 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Treatment titration and switch regimens as described by the prescribing clinician

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov